01 0126Z0.KS Samsung Epis Holdings Co., Ltd. Loading... : Bullish and Bearish Analyst Opinions

Epis Holdings has turned from its bottom and is now at a buyable level after a pullback from above 700,000 won. The biotech sector is rotating, and this stock's base formation suggests it is worth buying, though resistance overhead should be monitored.

Korean large-cap pharma/biotech companies like Celltrion, SK Biopharm, and Samsung Bioepis Holdings have the capital, BD capabilities, and R&D manpower to develop innovative first-in-class drugs. They are expected to produce novel therapies within about 3 years, matching China's rapid growth trajectory. These firms already have global tech-transfer track records and are building the ecosystem despite current stock underperformance.